| 前收市價 | 118.37 |
| 開市 | 118.03 |
| 買盤 | 119.76 x 200 |
| 賣出價 | 123.00 x 600 |
| 今日波幅 | 117.46 - 120.46 |
| 52 週波幅 | 76.53 - 131.49 |
| 成交量 | |
| 平均成交量 | 961,759 |
| 市值 | 28.539B |
| Beta 值 (5 年，每月) | 0.25 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.33 |
| 業績公佈日 | 2024年11月04日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2022年6月02日 |
| 1 年預測目標價 | 129.48 |
ReutersPfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
LONDON (Reuters) -Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer and BioNTech had filed their lawsuit in September 2022 over patents relating to messenger RNA (mRNA) technology, which underpins Pfizer and BioNTech's COVID-19 vaccine.
Yahoo FinanceStarboard Value takes $1 billion stake in Pfizer: Reports
An activist invester has taken interest in pharma giant Pfizer, which despite becoming a household name during the pandemic has struggled to move its stock.
ZacksARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
